Advertisement
Advertisement
U.S. markets open in 8 hours 18 minutes
Advertisement
Advertisement
Advertisement
Advertisement

AbCellera Biologics Inc. (ABCL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
13.54-0.14 (-1.02%)
At close: 04:00PM EDT
13.61 +0.07 (+0.52%)
After hours: 07:22PM EDT
Advertisement

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • F
    Fe
    Buyout by Lilly? Seems reasonable. Better buy now. Buyout price could be 10-fold.
  • P
    Prashant Parikh
    ABCL reminds me of the parable of the Golden Goose. While it might be attractive sell it off to the highest bidder (large pharma takeover) for an excellent price, we'd be much better served receiving a regular dose of golden eggs for the next two decades. I won't even consider touching this stock until it hits $108, unless something changes in the company's vision or execution.
    Bullish
  • P
    Prashant Parikh
    I had a thought that I'd like learned members to correct me on, if wrong. I don't think ABCL can be target for a takeover by any large pharma, because ABCL serves multiple players from Big Pharma, and that would not make sense, for say, Lilly (as an example) buying ABCL and doing drug discoveries for Pfizer, Merck, J&J, GSK etc. So in that light, a takeover would not make sense, which is mildly bad news, because while we don't want ABCL to be sold, we want people to "make offers" as a form of promotion and investor interest, to further ramp up prices. Thoughts?
  • J
    Jens
    Feeling very good about this stock, finally after holding at a huge loss for over a year.
  • P
    Pete
    Nice jump today! I'm about 6% from breaking even at my $12.79 cost basis. It's been a long year dropping all the way down, but I do think I will finish in the green by end of this year finally. Anyone who is in this for the COVID drugs will be sorely disappointed. Anyone who is in for the pipeline will love it.
    Bullish
  • P
    Prashant Parikh
    If anyone listened to Giada and other shorties, and sold yesterday at a low, we'd be down 25%.
    But even if the shorties were right, and the stock did crash, I was completely prepared for it. I'd just buy more. Because I care a hoot about what the price is today, tomorrow or even a week from now. I'm buying a piece of a company, not a stock, and I care for its long-term trajectory. As long as they do good work (which they are), their management remains robust (which it is), and they don't face a technological threat to their platform (which so far they haven't), there's no reason to sell. Just keep buying. My personal plan is to hold at least until the next 5-7 years, provided nothing substantial changes in the company. OK, signing off for a few days, spent too much time here. Good luck to us longs!
    Bullish
  • L
    Lawrence W.
    gained nearly 20% after the Reported a 66% increase in its Q2 revenue to $45.9 million from $27.6 million a year ago.
    Bullish
  • C
    Chris
    Lilly picks AmerisourceBergen for U.S. commercial rollout of COVID-19 antibody therapy
  • P
    Prashant Parikh
    What I'm looking for tomorrow
    1. New partnerships
    2. New molecules in clinic
    3. New program starts
    4. Progress on GMP / CMC facility and time-line
    5. New internal projects (such as the T-cells one they started earlier).
    6. Token revenue for early milestones

    What I'm not looking for
    1. Covid revenue from Lilly
    2. Eps hit or miss this quarter.
  • M
    Mad G
    Seems like ABCL is building an oncology program, sounds pretty exciting! The reward of this innovation could change the industry. Good luck to all.
  • J
    Joern
    WOW
    $1,022 million of cash
  • W
    William
    Wow…7.5 mil shares and up 20%+. I’m going to stop prognosticating so early in the day.
    Bullish
  • J
    Joern
    So what exactly was negative? IMHO everything is on track. Execution is flawless. Great mgmt team. Absolutely focused on building the platform and creating value. Their strategy is a no-brainer and will pay off. And the best: no funding worries. A balance sheet as strong as the Bank of Switzerland.
    Do 19M shorts want to change the narrative? Are they nervous? They better be.
    Because from here on it is a steady newsflow of more deals, more partnerships, more molecules in the clinic with funding secured. With the market recovering it will be a steady climb back to $20 EOY.
  • F
    Fe
    @giada

    You're a real professional investor and trader. Impressive how you contraindicate price movements on purpose to confuse people. 😂😂😂
  • W
    William
    • Total revenue of $46 million, compared to $28 million in Q2 2021
    • Four program starts in the quarter bringing cumulative total to 88, up 47% from Q2 2021
    • Net loss of ($0.02) per share (as expected) on a basic and diluted basis compared to ($0.01) (basic and diluted) per share in Q2 2021
  • W
    William
    Today’s volume says it all. 2.4 million and counting.
    Bullish
  • l
    luis
    Wohoo 15k shares finally green ! Been buying since 20 and average down to 11.88 finally pay day I will hold it till 33.33
  • P
    Prashant Parikh
    What is everyone's average purchase price here? I break even around $12.5 to $13. I'll keep accumulating as long as it stays below $12 in the near term.
  • W
    William
    Up nearly 21% for the week. I’ll take that and look for it to continue next week.
    Bullish
  • D
    Darwin
    Novavax plunges after cutting sales guidance in half for its COVID vaccine. Dang it.. wonder what this means for ABLC, is COVID going away? I’m optimistic that ABCL is going to continue generating profits off its COVID lineup while they work to get non-COVID molecules out for their partners!
    Bullish
Advertisement
Advertisement